Multiple Sclerosis and SARS-CoV-2 Vaccination: Considerations for Immune-Depleting Therapies

Several concerns have been raised about the use of immunodepleting agents including alemtuzumab, cladribine and CD20-depleting antibodies in people with multiple sclerosis (pwMS) during the coronavirus disease (COVID) 2019 pandemic. As the end of the pandemic is not yet in sight, vaccination against...

Descripción completa

Detalles Bibliográficos
Autores principales: Sellner, Johann, Rommer, Paulus S.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2021
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911298/
https://www.ncbi.nlm.nih.gov/pubmed/33525459
http://dx.doi.org/10.3390/vaccines9020099

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7911298/
https://www.ncbi.nlm.nih.gov/pubmed/33525459
http://dx.doi.org/10.3390/vaccines9020099

Ejemplares similares